TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) today announced that it has appointed Tricia Symmes to the position of Chief Operating Officer, effective November 1, 2016. In this newly created role, Ms. Symmes will lead all efforts related to the development and execution of the commercialization strategy for Acerus as well as have overall responsibility for business development and corporate communications.
"Tricia has an outstanding track record of success in the Canadian healthcare industry," said Tom Rossi, President and Chief Executive Officer of Acerus. "I am delighted that we were able to attract someone of Tricia’s calibre to our growing organization. She is a seasoned leader with nearly two decades of experience in prescription pharmaceuticals, OTC products, and medical devices across multiple therapeutic areas. I am confident that Tricia will provide the leadership and focus required to support our growth strategy and look forward to welcoming her to our team."
"It is exciting to be joining Acerus at such an important time and I look forward to working with the team to maximize our commercial opportunities and deliver value to customers, employees and shareholders," said Tricia Symmes, Acerus Chief Operating Officer.
Most recently, Ms. Symmes served as General Manager for Alcon Canada (a Novartis company). Prior to joining Alcon, Ms. Symmes held roles of increasing responsibility within Novartis Canada including, Vice President Sales, and Vice President Specialty Medicines. Ms. Symmes holds an MBA from Charles Sturt University (Australia), an Honours BSc. in Kinesiology (Western University), and a post-graduate Management Diploma in Human Resources (Humber College).
About Acerus
Acerus Pharmaceuticals Corporation is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.
Acerus currently markets two products in Canada: ESTRACE®, a product indicated for the symptomatic relief of menopausal symptoms; and NATESTO™, the first and only testosterone nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. Acerus’ pipeline includes two new innovative products: GYNOFLOR™, an ultra-low dose vaginal estrogen combined with a probiotic, used in the treatment of atrophic vaginitis, restoration of vaginal flora and treatment of certain vaginal infections; and TEFINA™, a ‘use as required’ drug development candidate, aimed at addressing a significant unmet need for women with female sexual dysfunction.
For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.
Notice Regarding Forward-Looking Statements
Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 1, 2016 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.
